Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/09/26	USD 1.235	+1.23%	2,570
25/09/26	USD 1.220	-0.81%	3,194
24/09/26	USD 1.230	-0.81%	23,032
23/09/26	USD 1.240	-3.88%	9,327
22/09/26	USD 1.290	+2.38%	17,205

Delayed Quote Nasdaq

More quotes

Market Closed - Nasdaq 06:30:00 29/09/26 am AEST			5-day change	1st Jan Change
1.235 ^USD	+1.23%		-1.98%	-77.21%

15/08	Exicure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
01/07	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026	CI

Market Cap	8.08M 7.11M 6.72M 6.1M 11.45M 776M 11.52M 80.5M 31.09M 396M 30.35M 29.69M 1.27B	P/E 2024	-2.88x	P/E 2025	-6.9x
Enterprise Value	4.51M 3.97M 3.75M 3.41M 6.4M 433M 6.43M 44.95M 17.36M 221M 16.95M 16.58M 711M	EV / Sales 2024	70.2x	EV / Sales 2025	-
Free-Float	58.53%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	XCUR	Delayed
CBOE	XCUR	Real-time
Deutsche Boerse AG	2H0	Delayed
Tradegate	2H0	Real-time
Börse Stuttgart	2H0	Delayed

15/08	Exicure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
01/07	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026	CI
30/05	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/04	Exicure announces co-development agreement with Adbiotech for burixafor (GPC-100)	RE
23/04	Exicure, Inc. And Adbiotech Co., Ltd. Enter Co-Development Agreement For Burixafor (GPC-100)	CI
11/04	Exicure, Inc. Announces Management Changes	CI
28/03	Exicure, Inc. Announces Resignation of Director Sangjin Yeo from Board and Audit Committee, Effective March 27, 2026	CI
26/03	Exicure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25/03	Exicure, Inc. Auditor Raises 'Going Concern' Doubt	CI
18/02	Exicure appoints Jung Soo Kim as CEO and president	RE
18/02	Exicure, Inc. Announces Executive Appointments, Effective February 11, 2026	CI
18/02	Exicure, Inc. Appoints Gyuyeob Lee as Interim Chief Financial Officer, Effective February 11, 2026	CI
18/02	Exicure, Inc. Appoints Jung Soo Kim as Chief Executive Officer, Effective February 11, 2026	CI

Exicure, Inc. Stock

Stocks

XCUR

US30205M3097

Biotechnology & Medical Research

Valuation: Exicure, Inc.

Chart: Exicure, Inc.

Latest news: Exicure, Inc.

Analysts' recommendations: Exicure, Inc.

Press Releases: Exicure, Inc.

News in other languages: Exicure, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Exicure, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

17/08/22	Chardan Adjusts Exicure's Price Target to $2 on 1-for-30 Reverse Stock Split, Maintains Neutral Rating	MT
29/03/22	Chardan Adjusts Exicure's Price Target to $0.25 From $0.40 'on Increased Dilution;' Neutral Rating Kept	MT
14/12/21	Chardan Downgrades Exicure to Neutral From Buy After Probe Shows Clinical Data Misrepresentation, Lowers PT to $0.40 From $2.25	MT
24/11/21	Chardan Adjusts Price Target on Exicure to $2.25 From $7 'on Uncertain Delays for Clinical Programs,' Keeps Buy Rating	MT
17/05/21	Exicure : HC Wainwright Adjusts Price Target on Exicure to $6 From $8, Maintains Buy Rating	MT

16/09	Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement	AQ
03/08	Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance	AQ
30/06	Exicure Announces Board and Committee Changes	AQ
11/06	Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement	AQ
02/06	Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q	AQ

02/08/21	Les valeurs à suivre aujourd'hui à Paris Lundi 2 août 2021
02/08/21	Ipsen : signe un partenariat avec Exicure dans les acides nucléiques sphériques
02/08/21	EN DIRECT DES MARCHES : Axa, Bolloré, Neoen, Ipsen, HSBC, Heineken, Square, Moderna...
02/08/21	Ipsen : accord de collaboration avec Exicure
02/08/21	Dernière ligne droite avant la coupure aoûtienne

1 day	+1.23%
1 week	-1.98%
Current month	-5.73%
1 month	-4.26%
3 months	-48.54%
6 months	-72.03%
Current year	-77.21%

1 week	1.17	1.29
1 month	1.17	1.6
Current year	1.05	6.64
1 year	1.05	9.48
3 years	1.05	36
5 years	1.05	195
10 years	1.05	975

Manager	Title	Age	Since
Jungsoo Kim CEO	Chief Executive Officer	-	11/02/2026
Gyuyeob Lee DFI	Director of Finance/CFO	40	11/02/2026
Josephine Cardarelli PSD	President	-	06/10/2025

Director	Title	Age	Since
Dong-Ho Lee BRD	Director/Board Member	64	21/08/2023
Gyeung Seog Cheon BRD	Director/Board Member	-	09/02/2026
Jungsoo Kim BRD	Director/Board Member	-	11/02/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
8/7/26	EXICURE HITRON, INC.	Others	Company	117,441	1.8589%
16/2/26	Josh Miller	Tax	Chief Accounting Officer	8	0.0001%	-
21/1/26	EXICURE HITRON, INC.	Sell	Company	258,367	4.0895%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXICURE, INC.	+1.23%	-1.98%	-67.59%	-65.69%	7.99M
WUXI APPTEC CO., LTD.	-0.37%	-3.67%	+57.21%	+87.75%	72.26B
ARGENX SE	-0.07%	-2.70%	+37.74%	+86.90%	60.24B
WUXI BIOLOGICS (CAYMAN) INC.	+0.75%	+0.75%	+36.71%	+21.09%	27.73B
INSMED INCORPORATED	-0.14%	-2.75%	-14.13%	+356.79%	25.73B
BIONTECH SE	+0.57%	+1.10%	+1.02%	-2.89%	24.75B
GENMAB A/S	+1.10%	+1.86%	+25.07%	-7.59%	20.74B
PHARMAESSENTIA CORPORATION	-1.70%	+0.43%	+150.24%	+323.16%	15.06B
EXELIXIS, INC.	+0.36%	+2.01%	+49.51%	+160.70%	14.41B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.53%	-8.15%	-6.38%	+483.59%	14.23B
Average	-0.08%	-0.29%	+26.94%	+144.38%	27.52B
Weighted average by Cap.	-0.12%	-1.08%	+38.13%	+127.84%

	2024	2025
Net sales	500K 440K 416K 377K 708K 48M 712K 4.98M 1.92M 24.49M 1.88M 1.84M 78.7M	-
Net income	-9.7M -8.53M -8.07M -7.32M -13.74M -931M -13.82M -96.6M -37.31M -475M -36.42M -35.63M -1.53B	-4.95M -4.35M -4.11M -3.73M -7.01M -475M -7.05M -49.25M -19.02M -242M -18.57M -18.17M -779M
Net Debt	-6.46M -5.69M -5.38M -4.88M -9.16M -620M -9.21M -64.37M -24.86M -317M -24.27M -23.74M -1.02B	-3.57M -3.14M -2.97M -2.69M -5.06M -343M -5.09M -35.55M -13.73M -175M -13.4M -13.11M -562M